Optimi Health Corp. Completes First Export of Psilocybin to the UK for Phase 2 Clinical Trial

Optimi Health Corp. has successfully completed its first export of naturally derived psilocybin to the United Kingdom. The shipment, consisting of psilocybin biomass and 5mg capsules, is intended to support a planned Phase 2 clinical trial in the UK. This export was authorized by Health Canada and the UK Home Office. The psilocybin product was manufactured at Optimi's GMP facility in Princeton, British Columbia, utilizing their proprietary extraction methods under a Health Canada Drug Establishment Licence. This achievement positions Optimi as a vertically integrated GMP supplier for regulated psychedelic research. The company also supplies psilocybin and MDMA drug products to regulated markets internationally, including Australia and Canada. Optimi Health Corp. is a commercial-stage pharmaceutical company focused on manufacturing GMP-grade psychedelic drug products for mental health therapies.